AXION
NHS
Extracorporeal technology in clinical development
Advancing blood-treatment technology for oncology and infectious disease
Axion Biomed is developing an extracorporeal platform designed to investigate circulating tumour cells and selected bloodborne pathogens, alongside commercial infection-control technologies.
Explore the platform
Clinical status
NHS trial approved · sponsor assigned
Commercial validation
Independent testing and NHS supply experience
Technology
Proprietary ROS-based platform
A platform spanning clinical development and commercial applications
Oncology Platform
Extracorporeal technology under clinical development, targeting circulating tumour cells and bloodborne pathogens.
Learn moreAir Treatment
Independently tested infection-control systems, certified and commercially supplied into NHS settings.
Learn moreWound Care
Smart-surface technology in development, giving long-lasting self-cleaning protection.
Learn more